Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 8/20 | 0.46 |
| ▸ | SRC | P12931 | 3/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.44 |
| ▸ | BCR | P11274 | 3/20 | 0.44 |
| ▸ | BRAF | P15056 | 5/20 | 0.43 |
| ▸ | EGFR | P00533 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1408098 | 0.92 | ABL1 (0.44) | ABL1SRCMKNK2MKNK1BCR | |
| SCHEMBL1408637 | 0.92 | ABL1 (0.54) | ABL1SRCBCRBRAFEGFR | |
| SCHEMBL1414442 | 0.92 | MKNK2 (0.53) | ABL1SRCMKNK2MKNK1BCR | |
| SCHEMBL2493761 | 0.92 | ABL1 (0.46) | ABL1SRCMKNK2MKNK1BCR | |
| SCHEMBL1408215 | 0.91 | MKNK2 (0.52) | ABL1SRCMKNK2MKNK1BCR | |
| SCHEMBL2502510 | 0.88 | ABL1 (0.44) | ABL1SRCMKNK2MKNK1BCR | |
| SCHEMBL1408446 | 0.84 | RET (0.48) | MKNK2MKNK1 | |
| SCHEMBL1408285 | 0.84 | SRC (0.53) | ABL1SRCBRAFEGFRKIT | |
| SCHEMBL1408518 | 0.84 | MKNK2 (0.52) | ABL1SRCMKNK2MKNK1BCR | |
| SCHEMBL1407966 | 0.83 | MKNK2 (0.63) | ABL1SRCMKNK2MKNK1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184561-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-07-19 | — | — | US | disclosed |
| US-8030311-B2 | Phenylacetamides suitable as protein kinase inhibitors | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| EP-1874770-B1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| US-20080319005-A1 | Phenylacetamides Suitable as Protein Kinase Inhibitors | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184561-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | MAP3K10, MAP3K20, MAP3K9 | ABL1 40/4885SRC 73/4885MKNK2 139/4885 |
| US-20080319005-A1 | Phenylacetamides Suitable as Protein Kinase Inhibitors | MAP3K20, MAP3K10, MAP3K9 | ABL1 38/4885SRC 88/4885MKNK2 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.